RHD positive haplotypes in D negative Europeans
© Wagner et al; licensee BioMed Central Ltd. 2001
Received: 24 April 2001
Accepted: 16 July 2001
Published: 16 July 2001
Blood group genotyping is increasingly utilized for prenatal diagnosis and after recent transfusions, but still lacks the specificity of serology. In whites, the presence of antigen D is predicted, if two or more properly selected RHD-specific polymorphism are detected. This prediction must fail, if an antigen D negative RHD positive allele is encountered. Excluding RHDψ and Cde S frequent only in individuals of African descent, most of these alleles are unknown and the population frequency of any such allele has not been determined.
We screened 8,442 antigen D negative blood donations by RHD PCR-SSP. RHD PCR positive samples were further characterized by RHD exon specific PCR-SSP or sequencing. The phenotype of the identified alleles was checked and their frequencies in Germans were determined.
We detected 50 RHD positive samples. Fifteen samples harbored one of three new D el alleles. Thirty samples were due to 14 different D negative alleles, only 5 of which were previously known. Nine of the 14 alleles may have been generated by gene conversion in cis, for which we proposed a mechanism triggered by hairpin formation of chromosomal DNA. The cumulative population frequency of the 14 D negative alleles was 1:1,500. Five samples represented a D+/- chimera, a weak D and three partial D, which had been missed by routine serology; two recipients transfused with blood of the D+/- chimera donor became anti-D immunized.
The results of this study allowed to devise an improved RHD genotyping strategy, the false-positive rate of which was lower than 1:10,000. The number of characterized RHD positive antigen D negative and Del alleles was more than doubled and their population frequencies in Europe were defined.
The antigen D encoded by the RHD gene is the most important blood group antigen determined by a protein. About 15% of whites are antigen D negative. Antigen D prediction by PCR was initially applied to fetus at risk for hemolytic disease of the newbom [1,2]. If serologic blood group typing cannot be performed with its usual ease, an RHD genotyping with a specificity and sensitivity comparable to serologic methods is of practical importance. For example, the utility of blood group genotyping in patients with recent transfusions was demonstrated by several studies [3,4,5,6].
The two RH genes, RHD and RHCE are about 30,000 bp apart , have opposite orientation [7,8] and are homologous retaining more than 90% identity . The most frequent cause for the absence of the antigen D in whites is the lack of the whole RHD gene  due to a deletion occurring in the Rhesus box . Therefore, most methods for antigen D prediction in whites probed the presence of RHD specific polymorphism [1,2,11,12,13]. Two RHD positive antigen D negative alleles are frequent in Africans: RHDψ carries a 37 bp insertion at the intron 3/exon 4 boundary and also harbors a stop codon ; Cdes is a RHD-CE-D hybrid gene [15,16,17]. In Asians, a major allele may be associated with a G314V missense mutation , and several other alleles may represent RHD-CE-D hybrid alleles [18,19,20].
In whites, RHD positive antigen D negative alleles were considered rare. However, the single systematic study  indicated a frequency of up to 22% among the rare haplotype Cde, which would render them the major cause of false-positive antigen D prediction by PCR in whites. The majority of RHD positive alleles in D negatives were reported as scattered case reports [22,23,24,25,26,27] with an often incomplete molecular work-up. The relative frequencies of these alleles and their cumulative population frequency remained unknown.
The specificity of RHD genotyping can be improved by a systematic characterization of RHD positive antigen D negative alleles. This rationale prompted us to determine the molecular causes of such alleles and their population frequencies in a random survey among European blood bank donors. We screened more than 8,000 antigen D negative blood donations by RHD PCR, including more than 700 rare Ccddee or ccddEe samples. Nine RHD-CE-D hybrid alleles, 5 other D negative and 3 D el alleles were identified. Five D positive donors missed by routine serology were uncovered. Two anti-D immunizations were traced. We established frequency estimates for RHD positive antigen D negative haplotypes in whites, which allowed us to devise an optimized RHD PCR strategy with an enhanced and defined specificity.
Population surveys of D negative blood donors documented D negative and screened by RHD PCR-SSP
Testing as single samples †
Testing as pools of 20 samples ‡
In a subsequent survey, we checked 7,374 ccddee samples, which were tested in pools of twenty samples for RHD promoter, intron 4 and exon 10. This survey aimed to increase the power of our study for ccddee donors, which represent 92% of all antigen D negative . Two RHD positive donors were detected (Table 1). In summary, 50 RHD positive donors were found in the two population surveys. They were further characterized by a detailed molecular work-up including RHD exon specific PCR-SSP, PCR of intron polymorphism or nucleotide sequencing.
Exclusion of five antigen D positive donors
The molecular and serologic work-up revealed that 5 donors, previously documented as antigen D negative, were weakly antigen D positive (Table 1). Two donors of phenotype CcDEe carried D category VI type I and weak D type 2, respectively. Two donors of phenotype ccDEe carried D category VI type I and the new partial D DIM , respectively. One donor of phenotype ccDee was a D+/- chimera.
Molecular analysis of 45 antigen D negative RHD gene positive samples
Del is defined by expressing trace amounts of antigen D that can be detected by an adsorption/elution study only . Because current routine serology cannot discriminate D negative from the Del phenotype, at least one RBC sample of each allele (Fig. 1) was tested by adsorption and elution. Three alleles represented the Del phenotype (Fig. 1B) and were characterized by one missense and two splice site mutations, respectively. For each allele, only a single sample was sequenced, and the influence of the mutations on mRNA splicing was not verified by cDNA analysis. Because lack of material, we could not formally exclude the Del phenotype for the two RHD-CE(2-7)-D1 samples (Fig. 1A). However, a Del expressed by this allele was very unlikely, as several other hybrid alleles carrying smaller gene conversions, like RHD-CE(2-7)-D2, were unequivocally D negative.
Estimated population frequencies for antigen D negative RHD positive and Del haplotypes in Europeans
95% confidence interval
D negative alleles
1:3,046 - 1:13,837
1:5,610 - 1:55,568
1:5,610 - 1:55,568
1:6,678 - 1:66,145
1:6,798 - 1:128,041
1:6,798 - 1:128,041
1:6,798 - 1:128,041
1:7,032 - 1:733,950
1:8,539 - 1:891,266
Cde or cdE
1:8,539 - 1:891,266
1:8,539 - 1:891,266
1:8,539 - 1:891,266
1:8,539 - 1:891,266
1:10,164 - 1:1,060,924
associated with Cde
associated with cdE
1:5,638 - 1:39,610
associated with cde
1:7,032 - 1:733,950
D el alleles
1:3,302 - 1:13,837
1:4,067 - 1:23,073
1:5,610 - 1:55,568
1:1,913 - 1:5,610
Analysis of SCARF samples
We obtained 2 ccddEE, 1 CcddEe and 1 ccddee (G+) DNA samples through the SCARF Exchange and tested them for promoter, intron 4, exon 7 and the 3' untranslated region by RHD PCR-SSP. Positive reactions were obtained with the CcddEe sample only, which was assigned to the RHD-CE(8-9)-D allele by RHD exon-specific PCR-SSP.
Optimized RHD PCR
Expected rates of false positive results and expected positive predictive values for differentRHD PCR strategies*
Positive predictive value
of positive result
Intron 4/Exon 7 
Intron 4/Exon 7/RHDψ 
Intron 4/Exon 7/W16X
Intron 4/Exon 7/Intron 7
Exons 3, 4, 5, 6, 7, 9 
Exons 2, 3, 4, 5, 6, 7, 9, 10 
Intron 4/Exon 7/W16X/RHDψ
Intron 4/Exon 7/Intron 7/W16X
Intron 4/Exon 7/Intron 7/W16X/RHDψ
Gene conversions in cis
In a systematic population survey including more than 8,000 antigen D negative blood donations, we identified 14 different RHD positive antigen D negative and 3 different Del haplotypes, the majority of which were novel. The molecular bases were alleles comprising RHD/RHCE hybrids, stop codons, missense mutations and splice site mutations. The cumulative frequency of RHD gene positive antigen D negative haplotypes was about 1:1,500; that of the D el alleles was about 1:3,000. We determined the specificity of antigen D prediction by PCR and devised an optimized RHD PCR strategy with a calculated positive predictive value greater than 0.9999. Five antigen D positive samples missed by routine D typing were uncovered and two anti-D immunizations traced.
For practical purposes, two groups of RHD alleles that do not express antigen D can be distinguished. RHD alleles of the first group lack some or many RHD specific polymorphism and usually represent RHD/CE hybrids. For alleles of this group, a correct antigen D prediction may be accomplished by a prudent selection of the RHD specific polymorphism utilized for RHD genotyping. RHD alleles of the second group carry all RHD specific polymorphism and most often harbor point mutations. For alleles of this group, a correct antigen D prediction necessitates the specific detection of an aberration that is usually unique to the allele. The identification of four new alleles in this group increased the number of known alleles from 3 to 7 and was critical for improving RHD genotyping.
The data of this study allowed for the first time to calculate population frequencies of RHD positive antigen D negative and D el alleles. This information was indispensable to derive rational RHD typing strategies and will be essential for establishing cost-efficient approaches. The majority of samples belonging to the first group of D negative alleles (probable RHD/CE hybrids) was compatible with RHD-CE-D hybrid alleles, in which the DNA segment derived from the RHCE gene encompassed at least exon 4 to exon 7. These samples would be correctly typed, if exon 4/intron 4 and exon 7 were used for RHD genotyping, as proposed previously . With the exception of RHD exon 9, testing additional RHD exons would not have improved the specificity of antigen D prediction. Improving this specificity, however, became possible by the specific detection of frequent alleles of the second group, like RHDψ and RHD(W16X). We demonstrated that testing 5 carefully selected polymorphism would have resulted in an assay yielding false positive results at a rate less than 1:12,000, and hence would have doubled the specificity compared to contemporary approaches testing all informative RHD exons [6,26]. Further improvements may be achieved by the specific detection of additional alleles, that might become practical in massively parallel molecular assays.
The detailed analysis including intron polymorphism revealed that the first group of alleles (probable RHD/CE hybrids) represented at least 9 different molecular events. We proposed that the proximity and inverse orientation of both RH genes favored gene conversions occurring in cis (Fig. 6), which have also been noted in partial D . An exact definition of the molecular bases of the RHD/CE hybrids would allow their specific detection, even if they were positioned in trans to the regular RHD allele. Such a detection would be necessary, if molecular RH zygosity testing is expected to achieve the same specificity as antigen D prediction.
A considerable proportion of seemingly D negative samples carrying the RHD gene presented a Del phenotype. Interestingly, RHD(M295I) coded for weak D, if associated with a ce haplotype , but for Del, if associated with a Ce haplotype; this observation may be explained by the suppressive effect of C in cis .
The nature and frequency of RHD gene positive antigen D negative alleles differ among populations. Apart from a probably lower absolute frequency, we detected in Europeans many parallels to oriental populations: Both populations shared the diverse nature of RHD haplotypes of the first group (probable RHD/CE hybrids) [18,19,20], the preferential occurrence of RHD positive antigen D negative alleles in Cde haplotypes , and the comparatively frequent observation of Del phenotypes . In contrast, RHDψ and Cde s are predominant in African populations . Still another situation may be present in the middle-west USA, where 6 of 26 RHD gene positive antigen D negative samples had aberrations limited to a single exon yet detectable by PCR .
Blood group serologists might note the observation of 5 D positive samples in our study with disturbance. In many centers, donors are checked for antigen D by sensitive methods at first and second donations only. On subsequent donations, carriers of partial D, like DvI or DIM, some weak D and D+/- chimerism may pass unnoticed in tests based on direct agglutination, even with the most avid IgM anti-D. Immunizations caused by units of such donors will generally be missed, because the occurrence of an anti-D in a patient is usually not further investigated . For example, the two anti-D immunizations induced by units of the chimerical donor of this study were found only in a look-back triggered by our molecular screen. Chimeras in the Rh system have repeatedly been observed [36,37] and chimeras may be a more widespread phenomenon than anticipated . A lower antigen density threshold for anti-D immunization has not been established yet, and future studies might indicate a need to exclude even Del donors from transfusion to D negative recipients. A routine investigation of all samples by adsorption and elution is not feasible. However, checking D-negative samples, especially those occurring with a C or E or both, for RHD specific sequences by nucleic amplification techniques may become practical in the near future. The knowledge of the detected alleles is also important for fetal genotyping assays using fetal DNA in maternal plasma, because false positive results will be obtained in mothers harboring RHD positive D negative alleles.
Subjects and Methods
EDTA- or citrate-anticoagulated blood samples were collected from blood donors characterized as D negative in routine typing including an antiglobulin test with anti-D. The D antigen determination in antiglobulin technique was performed as part of routine blood donor typing over a period of more than 15 years with varying commercial anti-D in tube or column agglutination. For each donor, this antiglobulin test was done only once, if the donor lacked the antigens C or E, and two times from independent samples, if the donor was either C or E positive. Subsequent donations were checked by direct agglutination using an Olympus PK7200 autoanalyzer only. Samples were collected at random for specific CcEe phenotypes. DNA was isolated by a modified salting-out procedure as described [27,39].
Screening by PCR with sequence specific priming (PCR-SSP)
For the first population survey, 314 ccddee, 433 Ccddee, 271 ccddEe, 19 CcddEe, 24 CCddee, 1 CcddEE and 6 ccddEE samples were tested individually for the presence of RHD specific polymorphism located in the RHD promoter, intron 4, exon 7 and the 3' untranslated region of exon 10 by PCR-SSP. The donor previously reported as "CCDnexee"  returned by chance and his allele was further characterized as RHD-CE(8-9)-D.
For the second population survey, 7,374 ccddee samples were analyzed in pools. Equal volumes of 20 samples were mixed. To confirm the sensitivity of the pool testing, 1% of D positive blood was added to an aliquot as positive control. DNA was extracted and checked for RHD promoter, intron 4, and exon 10 using modified PCR-SSP to enhance sensitivity. Repeated testing of donors was minimal, because the mandatory donation interval exceeded the collection period.
The donors were representative for the population currently living in the county of (Land) Baden-Württemberg. The ethnic origin of individual donors, in particular of those carrying Cde s or RHDψ was not identified. Independent of the population surveys, 2 ccddEE, 1 CcddEe and 1 ccddee DNA samples of unknown ethnic backgrounds were obtained from the SCARF Exchange (Hahnemann University, Philadelphia, USA).
Further molecular characterization
All samples positive for any of the above mentioned PCR-SSP assays were further investigated for the presence of RHD specific polymorphism in exon 3, exon 4, exon 5, exon 6, exon 7, and exon 9 by PCR-SSP. Samples positive for all PCR-SSP were sequenced, until they could be assigned to a distinct RHD allele. Samples negative for some PCR-SSP were checked for informative polymorphism in intron 1, intron 2, intron 7, intron 8, and intron 9.
Analysis for Cde s and RHDψ
RHD(N152T) and RHCE(L245V) present in Cde s  were checked by PCR-SSP. The 37 bp insertion present in RHDψ was detected by PCR-SSP. The 37 bp insertion, the M218I, F223V and S225F missense mutations and the Y269X nonsense mutation previously described for RHDψ  were confirmed by sequencing of all 10 exons; no additional aberrations were detected.
The ten RHD exons were sequenced as described [29,32]. The promoter was amplified with primers rend31k (for RHD alleles) or re04 (for RHCE) and rb45 and a DNA stretch encompassing primer re012 was sequenced using primers re08 and re09.
Most RHD PCR-SSP were similar to the RHD exon specific PCR-SSP previously described . Cycling conditions consisted of an initial denaturation of 2 min at 94°C, followed by ten cycles of 10 s denaturation at 94°C and 1 min annealing/extension at 65°C; and finally 25 cycles of 30 s denaturation at 94°C, 1 min annealing at 61°C and 30 s extension at 72°C. 0.4 U Taq polymerase (Qiagen, Hilden, Germany) were used in a final volume of 10 μl. Primers (Table 1) were re012 and re011d for the promoter; re41 and rb12 for intron 4; ga71 and ga72 for exon 7 in the PCR-SSP screening; rea7 and rr4 for exon 10; ga31 and rb21 for exon 3; ga41 and ga42 for exon 4; rb24 and ga51 for exon 5; ga62 and ga61 for exon 6; rb26 and re71 for exon 7 in the molecular work-up; re83 and re94 for exon 9; rb51 and rb52 for intron 7; RhPsiF and RhPsiB for RHDψ ; Rh152Tb and ga31 for RHD(N152T); and Rh223Vf and Rh245Vb for RHCE(L245V). Primer concentrations were 0.2 μM except for exon 6 (0.1 μM), RHD(N152T)(0.3 μM), and intron 7 and exon 9 (both 0.4 μM). For most samples intron 4/exon 7 was tested as multiplex reaction containing 0.2 μM of exon 7 (ga71/ga72) and 0.1 μM of intron 4 primers. As internal control, two primers amplifying an HGH gene fragment were added in concentrations of 0.05 μM for promoter, intron 4, and exon 7 (ga71/ga72); 0.075 μM for exon 10; 0.1 μM for intron 7, RHDψ, RHD(N152T) and RHCE(L245V); 0.15 μM for exon 3, exon 4, exon 7 (rb26/re71), and exon 9; 0.2 μM for exon 5 and exon 6. Mg2+ concentration was 0.15 μM, except 0.4 μM for intron 7. For exon 6, 20 % solution Q (Qiagen) was added. To enhance sensitivity, the pools were tested with RHD primers in a concentration of 0.3 μM and HGH primers at 0.1 μM.
Intron 1 was tested 1173 and 1174 bp 5' of the intron 1/exon 2 boundary by RHD specific amplification of exon 2 as described . Intron 2 was evaluated by PCR with length polymorphism as described . The BamH I restriction site introduced by the 9 bp deletion in RHD intron 8 position 1114 to 1122 (Genbank accession number AL139426) was checked after amplification with primers re74 and re93 and digestion with BamH I. The 980 bp deletion starting at position 633 in RHD intron 9 (Genbank accession number AL139426) was evaluated using primers re93k and re916.
Optimized RHD PCR-SSP for routine DNA typing
Reaction A contained primers ga71 and ga72 at 0.3 μM, rb12 and re41 at 0.1 μM, and HGH primers at 0.1 μM. Mg2+ was at 0.175 μM. Reaction B contained primers RhPsiF and RhPsiB at 0.5 μM, re11d and RhX1f1 at 0.3 μM, re721 and rb9 at 0.2 μM and as control primers rend9b1 and rend9b2 at 0.2 μM. Mg2+ was at 0.15 μM.
One sample of each RHD positive allele was evaluated by direct agglutination with two monoclonal anti-D (Seraclone anti-D, clone BS226; Biotest, Dreieich, Germany; and Frekaklon anti-D, clone MS201; Gull, Bad Homburg, Germany). Indirect antiglobulin test was done in a gel matrix test (LISS-Coombs 37°C, DiaMed-ID Micro Typing System, DiaMed, Cressier sur Morat, Switzerland) using an oligoclonal anti-D (Seraclone anti-D blend, clones H41 11B7, BS221 and BS232; Biotest). Samples reactive in gel matrix technique were further investigated using the monoclonal anti-D HM10, HM16, P3x61, P3x35, P3x212 11F1, P3x212 23B10, P3x241, P3x249, P3x290 (Diagast, Loos, France) and H41 11B7 (Biotest). The presence of a Del phenotype was determined by adsorption of 500 μl of a polyclonal anti-D (human incomplete anti-D; Lorne Laboratories, Reading, UK) to 500 μl packed red blood cells (RBC) for 1 h at 37°C and elution using a chloroform technique . A detailed serologic report of the RHD(C285Y) sample, dubbed DIM , has been published separately.
Flow cytometry was performed as described [40,41] using a polyclonal anti-D (anti-D Molter; Ortho Clinical Diagnostics, Neckarsgmünd, Germany) as primary and goat anti-human IgG, Fab-fragment, FITC-conjugated (Dianova, Hamburg, Germany) as secondary antibody. Markers were set to encompass >99.5% of a D positive control and less than 0.5% of a D negative control. The percentage of cells in the marker area was evaluated.
362 to 383
503 to 527
625 to 602
5 8 to 787
936 to 916
804 to 826
944 to 967
1066 to 1048
198 to 175
28 to 11
-53 to -34
-62 to -43
164 to 139
-3365 to - 3386
-3433 to -3409
-2498 to -2474
-858 to -879
-883 to -905
129 to 106
608 to 631
1,008 to 985
-244 to -224
-348 to -326
-54 to - 34
320 to 297
297 to 320
1216 to 1193
1689 to 1666
1311 to 1333
8506 to 8529
29489 to 29468
28840 to 28859
480 to 455
646 to 667
755 to 733
601 to 577
31 to 48
1,541 to 1,522
We thank E. Andreas Scharberg, Baden-Baden, Germany for supplying blood samples and Joann M. Moulds, Philadelphia, for rare DNA samples from the SCARF Exchange program, and Beate Wagner, Bremen, Germany, for helpful discussions. We acknowledge the expert technical assistance of Marianne Lotsch, Sabine Zahn, Anita Hacker, Sabine Kaiser and Katharina Schmid. This study was supported by the DRK-Blutspendedienst Baden-Württemberg, Stuttgart, Germany, and the Universitätsklinikum Ulm (Forschungsförderungsprojekt P.531), and the Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (Project DGTI/fle/00-01).
- Lo Y-MD, Bowell PJ, Selinger M, Mackenzie IZ, Chamberlain P, Gillmer MDG, Littlewood TJ, Fleming KA, Wainscoat JS: Prenatal determination of fetal RhD status by analysis of peripheral blood of rhesus negative mothers. Lancet. 1993, 341: 1147-1148. 10.1016/0140-6736(93)93161-S.View ArticlePubMed
- Bennett PR, Le Van Kim C, Colin Y, Warwick RM, Cherif-Zahar B, Fisk NM, Cartron JP: Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med. 1993, 329: 607-610. 10.1056/NEJM199308263290903.View ArticlePubMed
- Eshleman JR, Shakin-Eshleman SH, Church A, Kant JA, Spitalnik SL: DNA typing of the human MN and Ss blood group antigens in amniotic fluid and following massive transfusion. Am J Clin Pathol. 1995, 103: 353-357.PubMed
- Legler TJ, Eber SW, Lakomek M, Lynen R, Maas JH, Pekrun A, Repas-Humpe M, Schroter W, Kohler M: Application of RHD and RHCE genotyping for correct blood group determination in chronically transfused patients. Transfusion. 1999, 39: 852-855. 10.1046/j.1537-2995.1999.39080852.x.View ArticlePubMed
- Reid ME, Rios M, Powell VI, Charles-Pierre D, Malavade V: DNA from blood samples can be used to genotype patients who have recently received a transfusion. Transfusion. 2000, 40: 48-53. 10.1046/j.1537-2995.2000.40010048.x.View ArticlePubMed
- Rozman P, Dove T, Gassner C: Differentiation of autologous ABO, RHD, RHCE, KEL, JK, and FY blood group genotypes by analysis of peripheral blood samples of patients who have recently received multiple transfusions. Transfusion. 2000, 40: 936-942. 10.1046/j.1537-2995.2000.40080936.x.View ArticlePubMed
- Wagner FF, Flegel WA: RHD gene deletion occurred in the Rhesus box. Blood. 2000, 95: 3662-3668.PubMed
- Suto Y, Ishikawa Y, Hyodo H, Uchikawa M, Juji T: Gene organization and rearrangements at the human Rhesus blood group locus revealed by fiber-FISH analysis. Hum Genet. 2000, 106: 164-171. 10.1007/s004390051024.View ArticlePubMed
- Okuda H, Suganuma H, Kamesaki T, Kumada M, Tsudo N, Omi T, Iwamoto S, Kajii E: The analysis of nucleotide substitutions, gaps, and recombination events between RHD and RHCE genes through complete sequencing. Biochem Biophys Res Commun. 2000, 274: 670-683. 10.1006/bbrc.2000.3206.View ArticlePubMed
- Colin Y, Cherif-Zahar B, Le Van Kim C, Raynal V, van Huffel V, Cartron JP: Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by southern analysis. Blood. 1991, 78: 2747-2752.PubMed
- Aubin JT, Le Van Kim C, Mouro I, Colin Y, Bignozzi C, Brossard Y, Cartron JP: Specificity and sensitivity of RHD genotyping methods by PCR-based DNA amplification. Br J Haematol. 1997, 98: 356-364. 10.1046/j.1365-2141.1997.2193040.x.View ArticlePubMed
- Hyland CA, Wolter LC, Saul A: Identification and analysis of RH genes: application of PCR and RFLP typing tests. Transfus Med Rev. 1995, 9: 289-301.View ArticlePubMed
- Flegel WA, Wagner FF, Muller TH, Gassner C: Rh phenotype prediction by DNA typing and its application to practice. Transfus Med. 1998, 8: 281-302. 10.1046/j.1365-3148.1998.00173.x.View ArticlePubMed
- Singleton BK, Green CA, Avent ND, Martin PG, Smart E, Daka A, Narter-Olaga NG, LM Hawthorne, G Daniels: The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D- negative blood group phenotype. Blood. 2000, 95: 12-18.PubMed
- Blunt T, Daniels G, Carritt B: Serotype switching in a partially deleted RHD gene. Vox Sang. 1994, 67: 397-401.View ArticlePubMed
- Faas BHW, Becker EAM, Wildoer P, Ligthart PC, Overbeeke MAM, Zondervan HA, von dem Borne AEGK, van der School CE: Molecular background of VS and weak C expression in blacks. Transfusion. 1997, 37: 38-44. 10.1046/j.1537-2995.1997.37197176949.x.View ArticlePubMed
- Daniels GL, Faas BH, Green CA, Smart E, Maaskant-van Wijk PA, Avent ND, Zondervan HA, von dem Borne AE, van der School CE: The VS and V blood group polymorphisms in Africans: a serologic and molecular analysis. Transfusion. 1998, 38: 951-958. 10.1046/j.1537-2995.1998.381098440860.x.View ArticlePubMed
- Okuda H, Kawano M, Iwamoto S, Tanaka M, Seno T, Okubo Y, Kajii E: The RHD gene is highly detectable in RhD-negative Japanese donors. J Clin Invest. 1997, 100: 373-379.PubMed CentralView ArticlePubMed
- Sun C, Chou C, Lai N, Wang W: RHD gene polymorphisms among RhD-Negative Chinese in Taiwan. Vox Sang. 1998, 75: 52-57. 10.1159/000030958.View ArticlePubMed
- Lan JC, Chen Q, Wu DL, Ding H, Pong DB, Zhao T: Genetic polymorphism of RhD-negative associated haplotypes in the Chinese. J Hum Genet. 2000, 45: 224-227. 10.1007/s100380050006.View ArticlePubMed
- Avent ND, Martin PG, Armstrong-Fisher SS, Liu W, Finning KM, Maddocks D, Urbaniak SJ: Evidence of genetic diversity underlying Rh D negative, weak D (D") and partial D phenotypes as determined by multiplex PCR analysis of the RHD gene. Blood. 1997, 89: 2568-2577.PubMed
- Hyland CA, Wolter LC, Saul A: Three unrelated Rh D gene polymorphisms identified among blood donors with Rhesus CCee (r'r') phenotypes. Blood. 1994, 84: 321-324.PubMed
- Andrews KT, Wolter LC, Saul A, Hyland CA: The RhD- trait in a white patient with the RhCCee phenotype attributed to a four-nucleotide deletion in the RHD gene. Blood. 1998, 92: 1839-1840.PubMed
- Huang CH: Alteration of RH gene structure and expression in human dCCee and DCW- red blood cells: phenotypic homozygosity versus genotypic heterozygosity. Blood. 1996, 88: 2326-2333.PubMed
- Faas BHW, Beckers EAM, Simsek S, Overbeeke MAM, Pepper R, van Rhenen DJ, von dem Borne AEGK, van der School CE: Involvement of Ser103 of the Rh polypeptides in G epitope formation. Transfusion. 1996, 36: 506-511. 10.1046/j.1537-2995.1996.36696269508.x.View ArticlePubMed
- Maaskant-van Wijk PA, Faas BHW, de Ruijter JAM, Overbeeke MAM, von dem Borne AEGK, van Rhenen DJ, van der Schoot CE: Genotyping of RHD by multiplex polymerase chain reaction analysis of six RHD-specific exons. Transfusion. 1998, 38: 1015-1021. 10.1046/j.1537-2995.1998.38111299056309.x.View ArticlePubMed
- Gassner C, Schmarda A, Kilga-Nogler S, Jenny-Feldkircher B, Rainer E, Muller TH, Wagner FF, Flegel WA, Schonitzer D: RhesusD/CE typing by polymerase chain reaction using sequence-specific primers. Transfusion. 1997, 37: 1020-1026. 10.1046/j.1537-2995.1997.371098016439.x.View ArticlePubMed
- Wagner FF, Kasuike D, Kerowgan M, Flegel WA: Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in South-Western Germany. Infusionsther Transfusionsmed. 1995, 22: 285-290.PubMed
- Wagner FF, Frohmajer A, Ladewig B, Eicher NI, Lonicer CB, Müller TH, Siegel MH, Flegel WA: Weak D alleles express distinct phenotypes. Blood. 2000, 95: 2699-2708.PubMed
- Okubo Y, Yamaguchi H, Tomita T, Nagao N: A D variant, Del?. Transfusion. 1984, 24: 542-10.1046/j.1537-2995.1984.24685066827.x.View ArticlePubMed
- Wagner FF, Gassner C, Müller TH, Schönïtzer D, Schunter F, Flegel WA: Three molecular structures cause Rhesus D category VI phenotypes with distinct immunohematologic features. Blood. 1998, 91: 2157-2168.PubMed
- Wagner FF, Gassner C, Müller TH, Schönïtzer D, Schunter F, Flegel WA: Molecular basis of weak D phenotypes. Blood. 1999, 93: 385-393.PubMed
- Araszkiewicz P, Szymanski IO: Quantitative studies on the Rh-antigen D. Effect of the C gene. Transfusion. 1987, 27: 257-261. 10.1046/j.1537-2995.1987.27387235634.x.View ArticlePubMed
- Allen RW, Ward S, Harris R: Prenatal genotyping for the RhD blood group antigen: considerations in developing an accurate test. Genet Test. 2001, 4: 377-381. 10.1089/109065700750065126.View Article
- Flegel WA, Khull S, Wagner FF: Primary anti-D immunization by weak D type 2 RBC. Transfusion. 2000, 40: 428-434. 10.1046/j.1537-2995.2000.40040428.x.View ArticlePubMed
- Northoff H, Goldmann SF, Lattke H, Steinbach P: A patient, mosaic for Rh and Fy antigens lacking other signs of chimerism or chromosomal disorder. Vox Sang. 1984, 47: 164-169.View ArticlePubMed
- Salaru NN, Lay WH: Rh blood group mosaicism in a healthy elderly woman. Vox Sang. 1985, 48: 362-365.View ArticlePubMed
- van Dijk BA, Boomsma DI, de Man AJ: Blood group chimerism in human multiple births is not rare. Am J Med Genet. 1996, 61: 264-268. 10.1002/(SICI)1096-8628(19960122)61:3<264::AID-AJMG11>3.0.CO;2-R.View ArticlePubMed
- Miller SA, Dykes DD, Polesky HF: A simple salting-out procedure for extracting DNA from human nucleated cells. Nucl Acids Res. 1988, 16: 1215-1215.PubMed CentralView ArticlePubMed
- Wagner FF: Influence of Rh phenotype on the antigen density of C, c, and D: flow cytometric study using a frozen standard red cell. Transfusion. 1994, 34: 671-676. 10.1046/j.1537-2995.1994.34894353461.x.View ArticlePubMed
- Wagner FF, Flegel WA: Analysis by flow cytometry of chimerism after bone-marrow transplantation and of erythrocyte antigen density. In Aspects of the Flow-Cytometric Analysis of Red Blood Cells (Edited by Gutensohn K, Sonneborn H-H, Kuehnl P) Heidelberg, Clin Lab Publications. 1997, 95-103.
- Sachs L: Angewandte Statistik. 7th edition Berlin, springer. 1992
- Poulter M, Kemp TJ, Carritt B: DNA-based Rhesus typing: simultaneous determination of RHC and RHD status using the polymerase chain reaction. Vox Sang. 1996, 7: 164-168.View Article
- Simsek S, de Jong CAM, Cuijpers HTM, Bleeker PMM, Overbeeke MAM, Goldschmeding R, van der Schoot CE, von dem Borne AEGK: Sequence analysis of cDNA derived from reticulocyte mRNAs coding for Rh polypeptides and demonstration of E/e and C/c polymorphisms. Vox Sang. 1994, 67: 203-209.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.